Australian biotechnology company Antisense Therapeutics Limited (ASX: ANP) recently appointed Gil Price M.D., an experienced clinical physician trained in internal medicine, as a Consultant Medical Director. Dr Price has had a long-standing focus in drug development, adverse drug reactions, drug utilization and industry regulation.
Antisense Therapeutics is currently developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results.
In this video with ShareCafe’s Tim McGowen, Dr Price discusses his own history in the field of DMD with US firm Sarepta Therapeutics (US mkt cap $6.8bn) and more specifically what his role at Antisense involves.
Key points from the video:
- Dr Price’s previous experience with Sarepta Therapeutics and the similarities between Sarepta and Antisense
- The importance of robust clinical data and how that fits in with Antisense’s procedures
- The recent FDA Rare Disease Day Event and its implications for companies such as Antisense
- How the recent failure of one of Sarepta’s DMD studies has created an opportunity for ANP